Xbrane Biopharma: Framework Agreement with NHS - Redeye
Redeye reiterates its SEK173 base case following today’s announced Framework agreement with NHS and an eventful year ahead. We assess that it could generate more than SEK100m in royalties over the coming twelve months.
ANNONS
Redeye reiterates its SEK173 base case following today’s announced Framework agreement with NHS and an eventful year ahead. We assess that it could generate more than SEK100m in royalties over the coming twelve months.